Proteinase 3, Wegener's autoantigen: From gene to antigen

Journal of Leukocyte Biology

Volumn 69, Issue 2, 2001, Pages 177-190

  Van Der Geld, Y M ^a   Limburg, P C ^a   Kallenberg, C G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Myeloid leukemia; Serine protease; Wegener's granulomatosis

Indexed keywords

AZUROCIDIN; CATHEPSIN G; LEUKOCYTE ELASTASE; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; GENE CONTROL; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKEMIA CELL; MONOCYTE; MYELOID LEUKEMIA; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALS; AUTOANTIGENS; CHROMOSOME MAPPING; HUMANS; MYELOBLASTIN; PROTEIN PROCESSING, POST-TRANSLATIONAL; SERINE ENDOPEPTIDASES; WEGENER GRANULOMATOSIS;

EID: 0035117026     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (154)

1. The neutral proteases of human granulocytes. Isolation and partial characterization of granulocyte elastases
2. Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties
3. Subcellular localization and heterogeneity of neutral proteases in neutrophilic polymorphonuclear leukocytes
4. Subcellular location and properties of bactericidal factors from human neutrophils
5. Wegener's autoantigen decoded
6. Identity of Wegener's autoantigen (p29) with proteinase 3 and myeloblastin
7. Characterization of two azurphil granule proteases with active-site homology to neutrophil elastase
8. Wegener autoantigen and myeloblastin are encoded by a single mRNA
9. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters
10. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase
11. Antibiotic proteins of human polymorphonuclear leukocytes
12. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells
13. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years
14. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis
15. Wegener's granulomatosls autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils
16. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme
17. Association between active Wegener's granulomatosis and anticytoplasmic antibodies
18. Anti-neutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential
19. ANCA and predicting relapse in systemic vasculitis
20. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides
21. Limited prognostic value of changes in antineutrophil cytoplasmic antibody trier in patients with Wegener's granulomatosis
22. Rise in ANCA titer: To treat or not to treat
23. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG)
24. Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG)
25. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis
26. T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission
27. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells
28. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
29. Cytotoxic T lymphoeytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units
30. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxie T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia
31. Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia
32. Cloning of cDNA for proteinase 3: A serine protease, antibiotic, and autoantigen from human neutrophils
33. Localization of the gene encoding proteinase-3 (the Wegener's granulomatosis autoantigen) to human chromosome band 19p13.3
34. Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter
35. Genomic organization and chromosomal localization of the human cathepsin G gene
36. Structure of the human neutrophil elastase gene
37. The human neutrophil elastase gene. Analysis of the nucleotide sequence reveals three distinct classes of repetitive DNA
38. Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen
39. Chromosome aberrations and cancer
40. A myeloblastin/proteinase-3 cDNA clone identifies a BglII and a PvuII restriction fragment length polymorphism
41. Human cell lines U-937, THP-1 and Mono Mac 6 represent relatively immature cells of the monocyte-macrophage cell lineage
42. The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules
43. Regulation of myeloblastin messenger RNA expression in myeloid leukemia cells treated with all-trans retinoic acid
44. Myeloblastin/proteinase 3 belongs to the set of negatively regulated primary response genes expressed during in vitro myeloid differentiation
45. Functional interactions between bile acids, all-trans retinoic acid, and 1,25-dihydroxy-vitamin D3 on monocytic differentiation and myeloblastin gene down-regulation in HL60 and THP-1 human leukemia cells
46. Myeloperoxidase is a primary response gene in HL60 cells, directly regulated during hematopoietic differentiation
47. Human proteinase-3 expression is regulated by PU.1 in conjunction with a cytidine-rich element
48. Transcription factors, normal myeloid development, and leukemia
49. Chromosomal gene structure of human myeloperoxidase and regulation of its expression by granulocyte colony-stimulating factor
50. Changes in chromatin organization at the neutrophil elastase locus associated with myeloid cell differentiation
51. Cytosine demethylation of the proteinase-3/myeloblastin primary granule protease gene during phagocyte development
52. The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener's granulomatosis, and myeloperoxidase as shown by immunohistochemical studies on human leukemic cell lines
53. The polymorphonuclear leukocyte
54. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis
55. In situ localization by double-labeling immunoelectron microscopy of anti-neutrophil cytoplasmic autoantibodies in neutrophils and monocytes
56. The heterogeneity of azurophil granules in neutrophil promyelocytes: Immunogold localization of myeloperoxidase, cathepsin G, elastase, proteinase 3, and bactericidal/permeability increasing protein
57. Biosynthesis and processing of cathepsin G and neutrophil elastase in the leukemic myeloid cell line U-937
58. Processing of human cathepsin G after transfection to the rat basophilic/mast cell tumor line RBL
59. Characterization of the biosynthesis, processing, and sorting of human HBP/CAP37/azurocidin
60. Granules of the human neutrophilic polymorphonuclear leukocyte
61. Biosynthesis, processing and sorting of neutrophil proteins: Insight into neutrophil granule development
62. Processing and targeting of granule proteins in human neutrophils
63. Biosynthesis and processing of proteinase 3 in U937 cells. Processing pathways are distinct from those of cathepsin G
64. Characterization of the processing and granular targeting of human proteinase 3 after transfection to the rat RBL or the murine 32D leukemic cell lines
65. Zymogen activation specificity and genomic structures of human neutrophil elastase and cathepsin G reveal a new branch of the chymotrypsinogen superfamily of serine proteinases
66. An unusual specificity in the activation of neutrophil serine proteinase zymogens
67. Characterization of a recombinant proteinase 3, the autoantigen in Wegener's granulomatosis and its reactivity with antineutrophil cytoplasmic autoantibodies
68. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I
69. The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies
70. pH-dependent hysteretic behaviour of human myeloblastin (leucocyte proteinase 3)
71. Human cathepsin G lacking functional glycosylation site is proteolytically processed and targeted for storage in granules after transfection to the rat basophilic/mast cell line RBL or the murine myeloid cell line 32D
72. N-linked glycosylation of proteinase 3: Effect on enzymatic activity and targeting to granules
73. Carboxyl-terminal prodomain-deleted human leukocyte elastase and cathepsin G are efficiently targeted to granules and enzymatieally activated in the rat basophilic/mast cell line RBL
74. On the role of the preform-conformation for processing and intracellular sorting of human cathepsin G
75. A secreted preform of neutrophil proteinase 3 regulates the proliferation of granulopoietic progenitor cells
76. Presence of proteinase 3 in secretory vesicles: Evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules
77. The isoforms of human neutrophil elastase and cathepsin G differ in their carbohydrate side chain structures
78. Monocyte activation in patients with Wegener's Granulomatosis
79. Leucocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis
80. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo
81. Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties
82. Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool
83. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis
84. Comparison of properties of membrane bound versus soluble forms of human leukocytic elastase and cathepsin G
85. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors
86. Pathophysiology of ANCA-associated glomerulonephritis
87. Interaction of purified human proteinase 3 (PR3) with reconstituted lipid bilayers
88. Proteinase 3 interacts with a 111-kD membrane molecule of human umbilical vein endothelial cells
89. Evaluation of elastase and alpha 1-proteinase inhibitor-elastase uptake by polymorphonuclear leukocytes and evidence of an elastase-specific receptor
90. Surface expression of polymorphonuclear neutrophil (PMN) elastase: Beta 2-intergrins may function as binding site
91. Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis
92. A human renal cancer line as a new antigen source for the detection of antibodies to cytoplasmic and nuclear antigens in sera of patients with Wegener's granulomatosis
93. Signal transduction pathways of membrane expression of proteinase 3 (PR-3) in human endothelial cells
94. Wegener's granulomatosis: Anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response
95. Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3
96. ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells
97. Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC?
98. Myeloperoxidase binds to vascular endothelial cells, is recognized by ANCA and can enhance complement dependent cytotoxicity
99. Internalization of PR3 and MPO is concomitant with endothelial cell damage
100. Human neutrophil proteinase 3: Mapping of the substrate binding site using peptidyl thiobenzyl esters
101. Myeloblastin is a granulocyte colony-stimulating factor-responsive gene conferring factor-independent growth to hematopoietic cells
102. A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells
103. 28-kDa mammalian heat shock protein, a novel substrate of a growth regulatory protease involved in differentiation of human leukemia cells
104. Truncation of Sp1 transcription factor by myeloblastin in undifferentiated HL60 cells
105. Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins
106. Mechanisms for the microbicidal activity of cationic proteins of human granulocytes
107. Identification of the primary, antimicrobial domains in human neutrophil cathepsin G
108. Synthetic bactericidal peptide based on CAP37: A 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes
109. Proteinase-3 (PR-3): A polymorphonuclear leukocyte serine proteinase
110. The neutral proteases of human granulocytes. Isolation and partial characterization of two granulocyte collagenases
111. Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3
112. In vitro processing of human tumor necrosis factor-alpha
113. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3
114. Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation
115. Evidence for a crucial role of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of inflammation
116. Transforming growth factor-beta (TGF-beta) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
117. Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3
118. Proteinase 3. A neutrophil proteinase with activity on platelets
119. Specific inhibition of thrombin-induced cell activation by the neutrophil proteinases elastase, cathepsin G, and proteinase 3: Evidence for distinct cleavage sites within the aminoterminal domain of the thrombin receptor
120. Proteinase-activated receptors: Novel mechanisms of signaling by serine proteases
121. Cationic proteins of neutrophil azurophilic granules: Protein-protein interaction and blockade of NADPH oxidase activation
122. Anti-neutrophil cytoplasm antibodies can recognize vascular endothelial cell-bound anti-neutrophil cytoplasm antibody-associated autoantigens
123. Detachment and cytolysis of human endothelial cells by proteinase 3
124. Proteinase 3, the major autoantig en of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro
125. Proteinase 3 (PR3) upregulates ICAM-1 expression and induces VCAM-1 expression on human umblical vein endothelial cells (HUVEC): A possible role for PR3 in transmigration of leukocytes
126. Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase
127. Effect of anti-neutrophil cytoplasmic antibodies on proteinase 3-induced apoptosis of human endothelial cells
128. Proteotytically inactive C-terminal death domain of proteinase 3
129. Release of neutrophil proteinase 4(3) and leukocyte elastase during phagocytosis and their interaction with proteinase inhibitors
130. Elafin is a potent inhibitor of proteinase 3
131. Human myeloblastin (leukocyte proteinase 3): Reactions with substrates, inactivators and activators in comparison with leukocyte elastase
132. Effect of DNase on the activity of neutrophil elastase, cathepsin G and proteinase 3 in the presence of DNA
133. Measurements of proteinase 3 and its complexes with alpha 1-proteinase inhibitor and anti-neutrophil cytoplasm antibodies (ANCA) in plasma
134. Elevations of neutrophil proteinase 3 in serum of patients with Wegener's granulomatosis and polyarteritis nodosa
135. The alpha 1-antitrypsin gene and emphysema
136. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis
137. Strong link between the alpha 1-antitrypsin PiZ allele and Wegener's granulomatosis
138. Alpha 1-antitrypsin deficiency and anti-proteinase 3 antibodies in anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis
139. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele
140. Complexes between proteinase 3, alpha 1-antitrypsin and proteinase 3 anti-neutrophil cytoplasm autoantibodies: A comparison between alpha 1-antitrypsin PiZ allele carriers and noncarriers with Wegener's granulomatosis
141. The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis
142. alpha 1-Antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: Genetic and clinical implications
143. Alpha-1-antitrypsin phenotyping in ANCA-associated diseases: One of several arguments for protease/antiprotease imbalance in systemic vasculitis
144. alpha 1-Antitrypsin: Molecular pathology, leukocytes, and tissue damage
145. Proteolytic inactivation of alpha 1-antitrypsin and alpha 1-antichymotrypsin by neutrophils in arthritic joints
146. Alpha 1-proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase
147. Cleavage and inactivation of alpha 1-antitrypsin by metalloproteinases released from neutrophils
148. Tissue destruction by neutrophils
149. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin
150. Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis
151. Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis
152. ANCA-positive vasculitis and alpha 1-antitrypsin deficiency: Could free ANCA antigens released by neutrophils mediate vasculitic lesions?
153. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum
154. Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener's Granulomatosis